ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Development and validation of a predictive model for in-hospital mortality in patients with coronary heart disease and renal insufficiency.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary Heart Disease (CHD) with renal insufficiency is a significant global health issue. This study aimed to develop and validate a predictive model for in-hospital mortality to enable early risk identification in these patients. Methods: We analyzed data from 11,830 CHD patients with renal insufficiency treated at Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei Province, China (1994-2023). Among 113 clinical variables, five key features-age, high-sensitivity C-reactive protein (hs-CRP), estimated glomerular filtration rate (eGFR), creatine kinase (CK), and blood urea-were selected using Recursive Feature Elimination. Six machine learning models (Random Forest, XGBoost, Decision Tree, Neural Network, Logistic Regression, and Support Vector Machine) were developed and assessed for discrimination, calibration, and clinical utility. Temporal validation was performed using data from May 16, 2023 to October 31, 2024. SHapley Additive exPlanations (SHAP) were used for model interpretation. Results: Of the 11,830 patients, 694 (5.9 %) died during hospitalization. Among the six models, XGBoost showed the best overall performance in the test set, achieving the highest AUC (0.926), lowest Brier score (0.034), highest accuracy (0.957), and balanced sensitivity (0.381) and F1 score (0.512). Decision curve analysis confirmed its superior clinical utility. In a temporally independent validation cohort of 5983 patients, XGBoost maintained strong predictive performance (AUC = 0.901), demonstrating excellent robustness and generalizability. Conclusions: The XGBoost-based model accurately predicts in-hospital mortality in CHD patients with renal insufficiency, supporting early risk stratification and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.